Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Dev Neurobiol. Author manuscript; available in PMC 2010 November 1.
Published in final edited form as:
Dev Neurobiol. 2009 November; 69(13): 871–884.
doi: 10.1002/dneu.20747

Figure 5

An external file that holds a picture, illustration, etc.
Object name is nihms184568f5.jpg
VEGF neuroprotection against G93A-SOD1 in cultured primary MNs

(A) TUNEL labeling demonstrates increased DNA damage associated with 500 and 1000 pfu/MN AdmSOD transfection, which is significantly attenuated in the presence of VEGF (250 ng/ml). Transfection with equal concentrations of AdwtSOD1 does not result in increased DNA damage. MN densities are equivalent between treatments groups and results are averaged over at least 10 fields of 3 independent experiments and analyzed for statistical significance using one-way ANOVA followed by Tukey’s multiple comparison test (*P < 0.05). (B) Western blotting demonstrates decreased levels of G93A-SOD1-induced caspase-3 cleavage with VEGF treatment. Pretreatment (4 h pre) is the most efficacious, with decreased efficacy associated with VEGF cotreatment or posttreatment (18 h post).

Images in this article

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5
  • Figure 6
  • Figure 7
Click on the image to see a larger version.